concentrated oral gel

concentrated oral gel



(trade name)


Therapeutic: oral protectants
Pregnancy Category: UK


Management of oral pain due to:
  • oral mucositis/stomatitis (from chemotherapy or radiation),
  • irritation due to oral surgery,
  • traumatic ulcers caused by braces or poorly fitted dentures,
  • diffuse aphthous ulcers,
  • mouth ulcers caused by other diseases.


Adheres to oral mucosal surface, providing a protective mechanical barrier over ulcerated areas.

Therapeutic effects

Decreased pain from oral ulcers.


Absorption: Action is local.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (protectant effect)

POrapidunknownas long as application remains on oral surface


Contraindicated in: Hypersensitivity.
Use Cautiously in: None.

Adverse Reactions/Side Effects

None noted


Drug-Drug interaction



Oral (Adults) Use one packet 3 times daily, or as needed.


Concentrated oral gel: 15 mL packets in box of 21 packets

Nursing implications

Nursing assessment

  • Assess mouth ulcers prior to and periodically during therapy.
  • Assess severity of pain prior to and periodically during therapy.

Potential Nursing Diagnoses

Acute pain (Indications)


  • Pour entire contents of single-dose packet into glass and add 15 mL or 1 tbsp of water. If mixture is too thick, add additional 15–30 mL of water to achieve desired consistency. Stir well and use at once. Store at room temperature; do not refrigerate. Gel may become darker or thicker over time, but this does not affect efficacy or safety. Do not use packets that are split or torn or beyond expiration date.
  • If water is not available, may be used undiluted.
  • Oral: Administer 3 times daily or as needed.

Patient/Family Teaching

  • Instruct patient on preparing and using Gelclair. Rinse around mouth for at least 1 min or as long as possible to coat tongue, palate, throat, inside of cheeks, and all oral tissue thoroughly. Gargle and spit out. Advise patient that no adverse effects are expected if Gelclair is swallowed accidently. Instruct patient not to eat or drink for at least 1 hr after treatment.
  • Instruct patient to keep product out of direct sunlight and to store at room temperature.

Evaluation/Desired Outcomes

  • Decrease in pain from oral ulcers. If no improvement in 7 days, notify health care professional.
References in periodicals archive ?
Mucotrol(TM) is a concentrated oral gel wafer that was designed as a method of pain management for patients suffering from Oral Mucositis.
In addition to the apoptosis platform, Cell Pathways markets Gelclair(TM) Concentrated Oral Gel manufactured by Sinclair Pharma, Ltd.
a New Jersey based pharmaceutical marketing company, to distribute, promote and sell its Mucotrol(TM) concentrated oral gel wafer for the management and relief of pain from oral lesions associated with oral mucositis/stomatitis in the United States.
Revenues recognized on sales of Gelclair(TM) Concentrated Oral Gel for the first quarter of 2003 were $522,000.
Mucotrol(TM) concentrated oral gel wafer has a mechanical action indicated for the management and relief of pain by adhering to the mucosal surface of the mouth and soothing oral lesions of various origins including oral mucositis/stomatitis, which may be caused by chemotherapy or radiotherapy, irritation due to oral surgery and traumatic ulcers caused by braces or ill fitting dentures or diseases.
marketing rights to Gelclair(TM) Concentrated Oral Gel, a recently approved product for controlling the oral pain, including that resulting from oral mucositis -- a common and debilitating side effect of many chemotherapies and radiation therapy to the head and neck.
As announced earlier this week, the company plans to continue marketing Gelclair(TM) Concentrated Oral Gel to the oncology community through its partnership with Celgene Corporation (Nasdaq: CELG).
Nasdaq:CLPA) today announced the signing of a three-year agreement with Celgene Corporation (Nasdaq:CELG) aimed at broadening physician awareness and sales of Gelclair(TM) Concentrated Oral Gel within the U.
Butler Company, a leading international supplier of oral health care products, for Gelclair(TM) Concentrated Oral Gel.
Nasdaq:CLPA) today announced that the company is initiating an early experience program targeting 100 of the leading oncology physicians treating patients with oral mucositis, and has begun filling distribution channels in preparation for the June 3 formal launch of Gelclair(TM) Concentrated Oral Gel to the U.